 Eloxx Pharmaceuticals, Inc., ELOX a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat cystic fibrosis and other diseases caused by nonsense mutations limiting production of functional proteins, today announced that enrollment in its Phase 2 clinical trial for ELX-02 in cystic fibrosis has been resumed in Israel and Europe after being temporarily paused in response to the COVID-19 pandemic. We are pleased that enrollment in our Phase 2 clinical trial in cystic fibrosis has been resumed in Israel and Europe, however, our U.S. trial remains temporarily paused due to the COVID-19 pandemic as the health and safety of our employees, healthcare workers, and patients must be our highest priority during this crisis, said Dr. Gregory Williams, Chief Executive Officer of Eloxx. 